2278244-14-5
Chemical Structure
Nivatrotamab
Synonym(s): Hu3F8-BsAb
- CAS No.: 2278244-14-5
- Formula:N/A
- Molecular Weight:(200.87 kDa)
IUPAC Name: ((2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-2-yl)methyl 1H-pyrrole-2-carboxylate
SMILES: [Nivatrotamab]
Biological Activity: Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nivatrotamab | 99.00% | Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nakajima M, et al. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody. Pediatric blood & cancer. 2021 Jul;68(7):e28971. [Content Brief]
- [2]. Xu H, et al. A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy[J]. Oncoimmunology, 2021, 10(1): 1893500.
- [3]. Xu H, et al. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer immunology research. 2015 Mar;3(3):266-77. [Content Brief]
- [4]. Park JA, et al. Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jun 01;38(16):1836-1848. [Content Brief]
Keywords
